Can enasidenib cure leukemia?

Enasidipine (enasidenib) belongs to a class of drugs called isocitrate dehydrogenase -2 (IDH2) inhibitors and is used to treat relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutations. Ensidipine works by slowing or stopping the growth of cancer cells.

Ensidipine does not cure leukemia but may prolong survival. Trial data show that after receiving 6 months of treatment, approximately 19% of patients achieved complete remission, and the median duration of response was 8.2 months. Clinical data are quite optimistic.

Before takingensidipine, tell your doctor and pharmacist ifthe patient is allergic toensidipine, any other medicine, or any ingredient inensidipine tablets. Tell your doctor about the prescription and over-the-counter drugs, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change your medication dosage or carefully monitor for side effects. Tell your doctor if you are pregnant, planning to become pregnant, or planning to have a baby. Use effective contraception during treatment with ensidipine and for one month after the last dose. If the patient is male and the partner may become pregnant, effective contraception should be used during treatment and for one month after the last dose. Ensidipine may reduce the effectiveness of some oral contraceptives, so talk to your doctor about contraceptive methods that are suitable for you. Tell your doctor if you are breastfeeding, you should not breastfeed while you are takingensidipineand for one month after the last dose. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.